Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Alterity Therapeutics Investor Presentation

April 10, 2019August 16, 2022 Alterity Therapeutics

Alterity Therapeutics Investor Presentation 10 April 2019

2019

Post navigation

Alterity Therapeutics Launches to Asian Investors

Alterity Therapeutics presents at the American Academy of Neurology Annual Meeting

Related Posts

Appendix 4C – Q1 FY24 Quarterly Cash Flow Report

October 30, 2023March 10, 2025

HCW&Co publishes Prana Reach2HD trial report, results “beat expectations”

February 24, 2014August 16, 2022

Alterity Therapeutics meeting with US FDA provides development pathway for ATH434

June 30, 2020August 16, 2022

Recent Posts

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy
Alterity Therapeutics Raises A$40.0 million in Placement
Alterity Therapeutics Announces Funding to Accelerate ATH434 Clinical and Business Development Activities
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065